8,189 Zimmer Biomet Holdings, Inc. $ZBH Shares Acquired by Minneapolis Portfolio Management Group LLC

Minneapolis Portfolio Management Group LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 2.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 300,988 shares of the medical equipment provider’s stock after purchasing an additional 8,189 shares during the period. Zimmer Biomet accounts for approximately 2.4% of Minneapolis Portfolio Management Group LLC’s holdings, making the stock its 25th biggest position. Minneapolis Portfolio Management Group LLC’s holdings in Zimmer Biomet were worth $26,737,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Zimmer Biomet in the second quarter worth about $1,344,282,000. Primecap Management Co. CA bought a new stake in Zimmer Biomet in the second quarter worth $328,578,000. Bank of America Corp DE purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth about $187,480,000. Equity Investment Corp purchased a new position in shares of Zimmer Biomet during the second quarter valued at approximately $144,748,000. Finally, Legal & General Group Plc bought a new position in Zimmer Biomet in the 2nd quarter valued at $126,167,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In related news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ZBH. UBS Group raised their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 5th. Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Finally, Weiss Ratings upgraded Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Seven research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $112.74.

Check Out Our Latest Analysis on Zimmer Biomet

Zimmer Biomet Stock Performance

NYSE ZBH opened at $103.18 on Monday. The stock has a market capitalization of $19.53 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.42 and a beta of 0.50. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $112.54. The company has a current ratio of 1.46, a quick ratio of 0.79 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average of $95.76 and a 200 day moving average of $92.57.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2.04 billion. During the same quarter in the prior year, the business posted $1.90 earnings per share. Zimmer Biomet’s revenue for the quarter was up 3.1% on a year-over-year basis. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.56 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 24.30%.

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

See Also

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.